Ochratoxicosis in Beagle dogs. I. Clinical and clinicopathological features.
D000284:Administration, Oral; D000410:Alanine Transaminase / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000821:Animal Feed; D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D001230:Aspergillus / Q000254:growth & development; D001786:Blood Glucose / Q000032:analysis; D001831:Body Temperature; D001835:Body Weight; D003231:Conjunctivitis / Q000662:veterinary; D004283:Dog Diseases / Q000139:chemically induced*; D004285:Dogs; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007958:Leukocyte Count; D008297:Male; D009793:Ochratoxins / Q000008:administration & dosage / Q000302:isolation & purification / Q000633:toxicity*; D012275:Oryza; D012964:Sodium / Q000097:blood; D014069:Tonsillitis / Q000662:veterinary; D014556:Urine / Q000032:analysis
D001786:Blood Glucose; D006454:Hemoglobins; D009793:Ochratoxins; D012964:Sodium; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase